10 results
To test the non-inferiority of the Synergy* abluminal coated everolimus eluting stent with bio-absorbable polymer from Boston Scientific compared to the Nobori* abluminal coated biolimus eluting stent with bio-absorbable polymer from Terumo in the…
The objective of the ABSORB PHYSIOLOGY is to evaluate the following in participants undergoing coronary artery scaffolding/stenting for significant coronary artery disease:• The acute (post-implantation) effect of an implanted BVS or mDES on…
The main objective of the present study is to investigate whether the ORSIRO coronary stent is non-inferior compared to the Xience coronary stent in patients with total coronary occlusions.
This protocol will compare clinical outcomes of the SUPRAFLEX and XIENCE drug-eluting stents in a broad patient and lesion population and will gain substantial additional information on patients in a real world setting. These data will also provide…
The aim of this study is to evaluate the effect of a single oral dose of TW001 on oxidative stress and pharmacokinetics with and without food. Dosing with an oral solution is considered to have major advantages over iv dosing in a chronic condition…
Primary objective:The main objective of the present trial are:• to evaluate the effect of TW001 on oxidative stress biomarkers• to evaluate the safety of TW001 in patients with Alzheimer*s DiseaseSecondary objective:The secondary objective of the…
To evaluate the long-term safety of FAB122 in patients with ALS.
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
To assess the effect of treatment with 100 mg of FAB122 (edaravone) on disease progression in patients with ALS.
The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable CRLM (<=3cm) and no extrahepatic disease.